| Popis: |
Background: Growth hormone deficiency treatment involves daily injections, which can be difficult to administer, incorporate into daily routines, and lead to poor treatment compliance. The Treatment Burden–Child Growth Hormone Deficiency (TB-CGHD) measure was developed according to FDA and EMA regulatory guidance to assess key aspects of GHD treatment burden experience in children. There are two versions of the measure: self-report (PRO) for children 9 to 0.70) as was test-retest for the Total, PHYS and EWB domains (ICC >0.70) and slightly lower than expected for INT (0.64). At least one of the convergent validity hypotheses for total and domains were significant. For known-groups validity, TB-CGHD discriminated between length of time to administer injections (p |
